John Fani Srour, MD
Interventional Cardiology · Huntersville, NCNPI 1982633178
Payments from drug & device makers
Across 315 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$1K
- Johnson & Johnson$1K
- Abbott$1000
- Pfizer$571
- Novartis$493
- Heartflow, Inc.$445
- plus $3K from 26 others
What the payments were for
- Consulting fees$1,37517%
- Travel & lodging$721%
- Food & beverage$6,84782%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 1 | $1,375 |
| Johnson & Johnson | 86 | $1,350 |
| Abbott | 25 | $1,000 |
| Pfizer | 29 | $571 |
| Novartis | 25 | $493 |
| Heartflow, Inc. | 17 | $445 |
| Boston Scientific | 6 | $380 |
| AstraZeneca | 16 | $361 |
| Boehringer Ingelheim | 9 | $309 |
| Merck | 16 | $292 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $269 |
| Amgen | 14 | $234 |
| Abiomed | 3 | $153 |
| Medtronic(2 entities) | 7 | $152 |
| Bayer | 6 | $124 |
| Tactile Systems Technology Inc | 5 | $119 |
| Scpharmaceuticals Inc. | 4 | $117 |
| Novo Nordisk | 7 | $111 |
| Cvrx, Inc. | 3 | $66 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $61 |
| Actelion Pharmaceuticals US, Inc. | 3 | $60 |
| Bridgebio Pharma, Inc. | 3 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Kestra Medical Technology Services, Inc. | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| AbbVie | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Smith+Nephew | 1 | $18 |
| ZOLL Circulation Inc | 1 | $18 |
| Inari Medical, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$260
- XARELTO$251
- CROSSBOSS$160
- CardioMEMS HF System$124
- Xience V coronary stent system$120
- WAINUA$113
- VYNDAQEL$112
- WATCHMAN FLX$112
- JARDIANCE$105
How this compares
$8,321 in reported general payments places this provider in the 45th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 369 | $391,960 |
| EntrestoSacubitril/Valsartan | 189 | $197,843 |
| XareltoRivaroxaban | 143 | $145,514 |
| OzempicSemaglutide | 71 | $96,803 |
| JardianceEmpagliflozin | 67 | $80,147 |
| BrilintaTicagrelor | 89 | $71,788 |
| CamzyosMavacamten | 11 | $71,061 |
| MounjaroTirzepatide | 65 | $64,447 |
| Repatha SureclickEvolocumab | 88 | $63,927 |
| FarxigaDapagliflozin Propanediol | 45 | $54,268 |
| Praluent PenAlirocumab | 25 | $26,678 |
| Repatha SyringeEvolocumab | 12 | $6,766 |
| Icosapent Ethyl | 11 | $6,136 |
| Ranolazine ErRanolazine | 39 | $5,127 |
| Metoprolol Succinate | 452 | $4,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $571 | $391,960369 claims |
| NovartisEntresto | $493 | $197,843189 claims |
| Johnson & JohnsonXarelto | $1,350 | $145,514143 claims |
| AstraZenecaBrilinta, Farxiga | $361 | $126,056134 claims |
| Novo NordiskOzempic | $111 | $96,80371 claims |
| Boehringer IngelheimJardiance | $309 | $80,14767 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $12 | $71,06111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Huntersville
- Ravish SacharRaleigh$10.1M
- George AdamsGarner$5.2M
- Paul MahoneyGreenville$3.9M
- Oluseun AlliCharlotte$2.3M
- Patrick SimpsonPinehurst$1.6M
- Matthew CavenderChapel Hill$1.5M
- Rajesh SwaminathanDurham$1.4M
- Steven FilbyPinehurst$1.3M
- John PasquiniCharlotte$1.3M
- James ZidarRaleigh$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.